Aethlon Medical Reports Second Quarter Fiscal 2027 Results and Provides Corporate Update
AETHLON MEDICAL INC (AEMD) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Aethlon Medical Reports Second Quarter Fiscal 2027 Results and Provides Corporate Update SAN DIEGO, November 12, 2026 -- Aethlon Medical, Inc. (the Company or Aethlon) (Nasdaq: AEMD), a clinical-stage medical therapeutic company, today announced financial results for
How this was made
The 30-second read
Why it matters
The merger announcement introduces execution risk and potential dilution, while the Q2 results show a sharp rise in expenses and modest cash, suggesting near‑term financing pressure.
Market read
The new merger agreement and Q2 results provide fresh material for traders to assess AEMD's short‑term risk and potential long‑term upside.
What to watch
The contingent value rights (CVR) may provide future upside if the legacy business is monetized, which could mitigate current dilution concerns.
Background
Aethlon Medical (Nasdaq: AEMD) is a clinical‑stage company focused on its Hemopurifier device. The filing includes Q2 financials and a merger plan with North Immunology.
Ticker impact
SEC 8‑K filing announces a definitive merger agreement with North Immunology and provides Q2 fiscal 2027 results.
likely downside as market prices in merger‑related dilution and higher expenses
The merger is newly disclosed, carries execution risk, and the company reports a 77% rise in operating expenses and limited cash, suggesting near‑term weakness.
Market effects
Potential consolidation in the niche medical‑device/viral‑purification sector could affect peers developing similar technologies.
Limited to U.S. biotech investors; no broader regional effect.
Low global impact beyond specialty biotech space.
Counterpoint
If the merger succeeds, the combined entity could unlock value from the Hemopurifier platform, offering upside despite short‑term dilution.
Key entities
- companyAethlon Medical, Inc.
Nasdaq‑listed clinical‑stage medical‑device firm.
- companyNorth Immunology, Inc.
Merger partner; will become the surviving entity.

